A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta, or TGF-ß, family of proteins. We are a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, we have discovered and are developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Our lead product candidate, rinvatercept (KER-065), is being developed for the treatment of neuromuscular diseases.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 244M | 244M | - | - | 0 | - |
| Net Income | 87M | 87M | -187M | -153M | -105M | -59M |
| EPS | $2.30 | $2.30 | $-5.00 | $-5.20 | $-4.15 | $-2.52 |
| Free Cash Flow | 106M | 106M | -163M | -127M | -71M | -63M |
| ROIC | 196.3% | 14.6% | -32.8% | -46.1% | -37.7% | -22.1% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.06 | 0.06 | 0.03 | 0.04 | 0.05 | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 68M | 68M | -211M | -170M | -115M | -56M |
| Operating Margin | 27.7% | 27.7% | - | - | - | - |
| ROE | 28.7% | 19.9% | -32.8% | -46.1% | -37.7% | - |
| Shares Outstanding | 38M | 38M | 37M | 29M | 25M | 23M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 10M | 0 | N/A | 0 | N/A | N/A | 244M | 244M |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 17M | 34M | 55M | 87M | 135M | 174M | 130M | 130M |
| SG&A | 3.2M | 13M | 21M | 28M | 35M | 41M | 47M | 47M |
| EBIT | -11M | -47M | -56M | -115M | -170M | -211M | 68M | 68M |
| Op. Margin | -105.6% | N/A | N/A | N/A | N/A | N/A | 27.7% | 27.7% |
| Net Income | -14M | -45M | -59M | -105M | -153M | -187M | 87M | 87M |
| Net Margin | -141.4% | N/A | N/A | N/A | N/A | N/A | 35.7% | 35.7% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||||
| ROIC | -96.4% | -17.3% | -22.1% | -37.7% | -46.1% | -32.8% | 14.6% | 196.3% |
| ROE | N/A | N/A | N/A | -37.7% | -46.1% | -32.8% | 19.9% | 28.7% |
| ROA | -129.0% | -16.8% | -23.0% | -34.1% | -41.3% | -30.4% | 18.2% | 25.7% |
| Cash Flow | ||||||||
| Op. Cash Flow | -16M | -37M | -62M | -70M | -125M | -161M | 108M | 108M |
| Free Cash Flow | -16M | -37M | -63M | -71M | -127M | -163M | 106M | 106M |
| Owner Earnings | -16M | -41M | -74M | -89M | -154M | -197M | 77M | 77M |
| CapEx | 271K | 294K | 1.0M | 1.2M | 2.5M | 1.9M | 1.6M | 1.6M |
| Maint. CapEx | 208K | 278K | 378K | 674K | 815K | 1.2M | 1.5M | 1.5M |
| Growth CapEx | 63K | 16K | 646K | 567K | 1.6M | 702K | 42K | 42K |
| D&A | 208K | 278K | 378K | 674K | 815K | 1.2M | 1.5M | 1.5M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.4% |
| Capital Allocation | ||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 375M | 375M |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 85.8% |
| Stock-Based Comp | 59K | 4.1M | 12M | 19M | 29M | 35M | 29M | 29M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||
| Net Debt | -13M | -531M | -459M | -545M | -648M | -1.1B | -558M | -271M |
| Cash & Equiv. | 7.0M | 266M | 230M | 279M | 331M | 560M | 287M | 287M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 17M |
| Debt/Equity | -0.07 | N/A | N/A | 0.05 | 0.04 | 0.03 | 0.06 | 0.06 |
| Interest Coverage | -1320.4 | -7776.2 | -14093.3 | -114790.0 | N/A | N/A | N/A | N/A |
| Equity | -19M | N/A | N/A | 277M | 332M | 572M | 303M | 303M |
| Total Assets | 11M | 269M | 255M | 307M | 370M | 616M | 338M | 338M |
| Total Liabilities | 30M | N/A | N/A | 29M | 38M | 44M | 35M | 35M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -20M | -65M | -124M | -228M | -381M | -569M | -482M | -482M |
| Working Capital | 4.4M | 261M | 240M | 269M | 323M | 561M | 295M | 295M |
| Current Assets | 8.9M | 268M | 251M | 286M | 347M | 589M | 315M | 315M |
| Current Liabilities | 4.5M | 7.2M | 12M | 17M | 24M | 27M | 20M | 20M |
| Per Share Data | ||||||||
| EPS | -6.08 | -2.93 | -2.52 | -4.15 | -5.20 | -5.00 | 2.30 | 2.30 |
| Owner EPS | -0.70 | -2.67 | -3.19 | -3.54 | -5.24 | -5.26 | 2.04 | 2.04 |
| Book Value | -0.84 | N/A | N/A | 11.00 | 11.29 | 15.25 | 8.01 | 8.01 |
| Cash Flow/Share | -0.69 | -2.38 | -2.67 | -2.78 | -4.23 | -4.29 | 2.84 | 2.34 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 23.3M | 15.5M | 23.3M | 25.2M | 29.4M | 37.5M | 37.8M | 37.8M |
| Valuation | ||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 5.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 4.1 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 2.5 |
| Price/Book | N/A | N/A | N/A | 4.2 | 3.6 | 1.1 | N/A | 1.4 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 1.8 |
| FCF Yield | N/A | -3.1% | -4.8% | -6.1% | -10.5% | -26.5% | N/A | 24.2% |
| Market Cap | N/A | 1.2B | 1.3B | 1.2B | 1.2B | 615M | 0 | 437M |
| Avg. Price | N/A | 44.49 | 50.87 | 44.25 | 40.79 | 53.77 | 0.00 | 11.55 |
| Year-End Price | N/A | 77.84 | 56.67 | 46.68 | 41.05 | 16.42 | 0.00 | 11.55 |
Keros Therapeutics, Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
Keros Therapeutics, Inc. trades at 7.4x trailing earnings, compared to its 15-year median P/E of 15.0x, suggesting it is currently Cheap relative to its historical range. Total shareholder yield (buybacks) is 85.8%.
Keros Therapeutics, Inc. (KROS) has a current P/E ratio of 7.4, compared to its historical median P/E of 15.0. The stock is currently considered Cheap based on its historical valuation range.
Keros Therapeutics, Inc. (KROS) has a 5-year average return on invested capital (ROIC) of -24.8%. This is below average and may indicate limited pricing power.
Keros Therapeutics, Inc. (KROS) has a market capitalization of $437M. It is classified as a small-cap stock.
Keros Therapeutics, Inc. (KROS) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 85.82%.
Based on historical P/E analysis, Keros Therapeutics, Inc. (KROS) appears cheap. The current P/E of 7.4 is 51% below its historical median of 15.0.
Keros Therapeutics, Inc. (KROS) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Keros Therapeutics, Inc. (KROS) reported annual revenue of $244 million in its most recent fiscal year, based on SEC EDGAR filings.
Keros Therapeutics, Inc. (KROS) has a net profit margin of 35.7%. This is a strong margin indicating high profitability.
Keros Therapeutics, Inc. (KROS) generated $106 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Keros Therapeutics, Inc. (KROS) has a debt-to-equity ratio of 0.06. This indicates a conservatively financed balance sheet.
Keros Therapeutics, Inc. (KROS) reported earnings per share (EPS) of $2.30 in its most recent fiscal year.
Keros Therapeutics, Inc. (KROS) has a return on equity (ROE) of 19.9%. This indicates the company generates strong returns for shareholders.
The Ledger Terminal provides 7 years of financial data for Keros Therapeutics, Inc. (KROS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Keros Therapeutics, Inc. (KROS) has a book value per share of $8.01, based on its most recent annual SEC filing.